Summary
PHARMARIVE has a registered holding activity and consists mainly of financial fixed assets; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €114,888 and a net result of -€19,028. Equity is shrinking by about 6.9% per year across the filed financial years. Its solvency ranks better than 18% of 12,686 sector peers (NACE 47, financial year 2025). The company has been active since 2013 and the Belgian Official Gazette contains no insolvency or warning signals.
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
22-08
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format · 22 days late
2025
27-09
NBB filing
Annual accounts filed
financial year 2024 · full format · 58 days late
2024
31-10
NBB filing
Annual accounts filed
financial year 2023 · full format · 92 days late
16-01
Gazette deed
Resignation: BLUESTONE (manager)Reappointment: BLUESTONE (director) · Permanent representative: Paul RANSART · Amendment of the articles13 facts ▸
Gazette deed
Resignation: BLUESTONE (manager)
Reappointment: BLUESTONE (director) · Permanent representative: Paul RANSART · Amendment of the articles13 facts ▸
- General meeting, 29-12-2023
- Amendment of the articles (2 times)
- Capital conversion, “compte de capitaux propres statutairement indisponible” (deed in French)
- Other provision, “suppression du compte de capitaux propres statutairement indisponible et mise à disposition pour distributions futures, supprimer le compte créé en application…” (deed in French)
- Other provision, “dispense de lecture du rapport justifiant la modification de l’objet, dispense le président de donner lecture” (deed in French)
- Purpose change
- Capital
- Director resignation, BLUESTONE (manager)
- Director reappointment, BLUESTONE (director (not named in the articles))
- Permanent representative, Paul RANSART
- Director discharge, BLUESTONE
- Registered office clause, “1040 Etterbeek, Rue Gérard 150” (deed in French)
- +1 further fact in this act
2023
31-12
Financial
Weakest financial yearnet -€49,435
Net result drops to -€49,435, the lowest in the series; recovery starts the following year.
06-10
NBB filing
Annual accounts filed
financial year 2022 · full format · 67 days late
2022
31-12
Financial
Back to profitnet €26,028
Net result €26,028 after 2 loss-making years.
23-12
NBB filing
Annual accounts filed
financial year 2021 · full format · 145 days late
2021
28-10
NBB filing
Annual accounts filed
financial year 2020 · full format · 89 days late
2020
30-11
NBB filing
Annual accounts filed
financial year 2019 · full format · 122 days late
2019
31-12
Financial
Equity above €200,000equity €213,815 ▲15.9%
A profit in every financial year since 2018 builds equity to €213,815.
09-08
NBB filing
Annual accounts filed
financial year 2018 · full format · 9 days late
2018
20-08
NBB filing
Annual accounts filed
financial year 2017 · full format · 20 days late
2017
07-09
NBB filing
Annual accounts filed
financial year 2016 · full format · 38 days late
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 13 annual accounts filed, the latest 10 are here; all 13 are under Financials.
1 of 3 deeds read
About the unread acts
Of the 3 Belgian Official Gazette deeds we know for this company, 1 has been read. The other 2 have not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.